Aug 08, 2018
Teva’s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical’s fremanezumab for treating migraine is expected to launch later this year. Celltrion disclosed that U.S. drug regulators issued a Form 483 for its plant in Incheon, South Korea on tuesdsy. Eight manufacturin...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper